drugset / Trial / NCT03547271

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

NCT03547271 ↗

Phase 3 Completed 1660 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Primary objective: This study aimed to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b \[DTaP-IPV-HB-Hib vaccine\]) to infants and toddlers 6 weeks to 18 months old Secondary objectives: This study aimed to demonstrate the non-inferiority of the antibody (Ab) response against meningococcal serogroups A, C, Y, and W following the administration of 2 doses in infancy of MenACYW conjugate vaccine compared to 2 doses of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and DTaP-IPV-HB-Hib vaccine) to infants and toddlers 6 weeks to 18 months old. \- This study aimed to describe the Ab responses against meningococcal groups A, C, Y, and W and the antigens of the routine pediatric vaccines administered in the study.

Timeline

Start
2018-12-14
Primary completion
2023-05-17
Completion
2023-05-24

Outcome

Mixed primary results

paper Non-inferiority of MenACYW-TT versus MCV4-TT, based on GMTs post-booster, was demonstrated for serogroups C, W, and Y but not for A. PMID 40665158 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject DTaP-IPV-HB-Hib vaccine Vaccine — —
Subject MMR vaccine Vaccine — —
Subject MenACYW conjugate vaccine Vaccine 0.5 ml Intramuscular
Comparator Nimenrix Vaccine 0.5 ml Intramuscular
Subject Pneumococcal vaccine (10-valent) Vaccine — —
Subject Pneumococcal vaccine (13-valent) Vaccine — —